Pippa Powell

Pippa Powell

Auto-generated profile, based on publicly available information

Pippa Powell

European Lung Foundation, Sheffield, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
GKGerard H Koppelman
Gerard H Koppelman
MPMaria Pino-Yanes
Maria Pino-Yanes
EMErik Melén
Erik Melén
PPPippa Powell
Pippa Powell
KBKen R. Bracke
Ken R. Bracke
GBGuy G Brusselle
Guy G Brusselle

9 August 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SJSadia Janjua
Sadia Janjua
PPPippa Powell
Pippa Powell
RARichard Atkinson
Richard Atkinson
ESElizabeth Stovold
Elizabeth Stovold
RFRebecca Fortescue
Rebecca Fortescue
Background More than 90% of the global population lives in areas exceeding World Health Organization air quality limits. More than four million people each year are thought to die early due to air pollution, and poor air quality is thought to reduce an average European's life expectancy by one year. Individuals may be able to reduce health risks through interventions such as masks, behavioural changes and use of air quality alerts. To date, evidence is lacking about the efficacy and safety of such interventions for the general population and people with long‐term respiratory conditions. This topic, and the review question relating to supporting evidence to avoid or lessen the effects of air pollution, emerged directly from a group of people with chronic obstructive pulmonary disease (COPD) in South London, UK. Objectives 1. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with or without chronic respiratory conditions to reduce their exposure to outdoor air pollution. 2. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with chronic respiratory conditions reduce the personal impact of outdoor air pollution and improve health outcomes. Search methods We identified studies from the Cochrane Airways Trials Register, Cochrane Central Register of Controlled Trials, and other major databases. We did not restrict our searches by date, language or publication type and included a search of the grey literature (e.g. unpublished information). We conducted the most recent search on 16 October 2020. Selection criteria We included randomised controlled trials (RCTs) and non‐randomised studies (NRS) that included a comparison treatment arm, in adults and children that investigated the effectiveness of an individual‐level intervention to reduce risks of outdoor air pollution. We included studies in healthy individuals and those in people with long‐term respiratory conditions. We excluded studies which focused on non‐respiratory long‐term conditions, such as cardiovascular disease. We did not restrict eligibility of studies based on outcomes. Data collection and analysis We used standard Cochrane methods. Two review authors independently selected trials for inclusion, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane Risk of Bias tool for RCTs and the Risk Of Bias In Non‐randomised Studies ‐ of Interventions (ROBINS‐I) as appropriate. One review author entered data into the review; this was spot‐checked by a second author. We planned to meta‐analyse results from RCTs and NRS separately, using a random‐effects model. This was not possible, so we presented evidence narratively. We assessed certainty of the evidence using the GRADE approach. Primary outcomes were: measures of air pollution exposure; exacerbation of respiratory conditions; hospital admissions; quality of life; and serious adverse events. Main results We identified 11 studies (3372 participants) meeting our inclusion criteria (10 RCTs and one NRS). Participants’ ages ranged from 18 to 74 years, and the duration of studies ranged from 24 hours to 104 weeks. Six cross‐over studies recruited healthy adults and five parallel studies included either people with pre‐existing conditions (three studies) or only pregnant women (two studies). Interventions included masks (e.g. an N95 mask designed to filter out airborne particles) (five studies), an alternative cycle route (one study), air quality alerts and education (five studies). Studies were set in Australia, China, Iran, the UK, and the USA. Due to the diversity of study designs, populations, interventions and outcomes, we did not perform any meta‐analyses and instead summarised results narratively. We judged both RCTs and the NRS to be at risk of bias from lack of blinding and lack of clarity regarding selection methods. Many studies did not provide a prepublished protocol or trial registration. From five studies (184 participants), we found that masks or altered cycle routes may have little or no impact on physiological markers of air pollution exposure (e.g. blood pressure and heart rate variability), but we are very uncertain about this estimate using the GRADE approach. We found conflicting evidence regarding health care usage from three studies of air pollution alerts, with one non‐randomised cross‐over trial (35 participants) reporting an increase in emergency hospital attendances and admissions, but the other two randomised parallel trials (1553 participants) reporting little to no difference. We also gave the evidence for this outcome a very uncertain GRADE rating. None of our included trials reported respiratory exacerbations, quality of life or serious adverse events. Secondary outcomes were not well reported, but indicated inconsistent impacts of air quality alerts and education interventions on adherence, with some trials reporting improvements in the intervention groups and others reporting little or no difference. Symptoms were reported by three trials, with one randomised cross‐over trial (15 participants) reporting a small increase in breathing difficulties associated with the mask intervention, one non‐randomised cross‐over trial (35 participants) reporting reduced throat and nasal irritation in the lower‐pollution cycle route group (but no clear difference in other respiratory symptoms), and another randomised parallel trial (519 participants) reporting no clear difference in symptoms between those who received a smog warning and those who did not. Authors' conclusions The lack of evidence and study diversity has limited the conclusions of this review. Using a mask or a lower‐pollution cycle route may mitigate some of the physiological impacts from air pollution, but...

1 May 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
SMSarah Masefield
Sarah Masefield
JEJessica Edwards
Jessica Edwards
KHKjeld Hansen
Kjeld Hansen
DHDominique Hamerlijnck
Dominique Hamerlijnck
KLKarin Lisspers
Karin Lisspers
PPPippa Powell
Pippa Powell
Asthma outcomes will be transformed if the priorities in the EARIP research roadmap are addressedhttp://ow.ly/9maP307TVNk

30 May 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MSMichaela Senek
Michaela Senek
DDDavid Drummond
David Drummond
HPHilary Pinnock
Hilary Pinnock
KHKjeld Hansen
Kjeld Hansen
AAAnshu Ankolekar
Anshu Ankolekar
PPPippa Powell
Pippa Powell
Background: Digital health technology adoption has accelerated in respiratory care, particularly since the COVID-19 pandemic, supporting various applications from self-management to telerehabilitation. While these technologies have transformed health care delivery, their impact on the patient-provider relationship in specialist respiratory care remains poorly understood. Objective: This study aims to systematically review the literature on the impact of digital health technology on the patient-provider relationship in respiratory secondary care settings and to understand the factors that enhance or diminish this relationship. Methods: In December 2023, we conducted a systematic review following Cochrane methodology, searching MEDLINE, Embase, CINAHL, Cochrane databases, and PsycINFO. We included qualitative, quantitative, and mixed methods studies examining digital health interventions in respiratory secondary care. Trained volunteers from the European Respiratory Society CONNECT Clinical Research Collaboration performed screening and data extraction. We conducted a qualitative meta-synthesis of findings, followed by an abductive quantitative data analysis. A total of 3 stakeholder workshops were held to interpret findings collaboratively with patients and health care professionals. Results: From 15,779 papers screened, 97 met the inclusion criteria (55 qualitative/mixed-methods studies, 42 quantitative studies). Studies covered various respiratory conditions, including COPD (32%), asthma (26%), and COVID-19 (13%). Four main themes emerged: trust (foundational to the relationship), adoption factors (including clinical context and implementation drivers), confidence in technology (based on functionality and the evidence base), and connection (encompassing communication and a caring presence). Digital health technology can either enhance or diminish trust between patients and clinicians, with patients' perceptions of the motivations behind its implementation being crucial. While technology facilitated access and communication, remote consultations risked depersonalisation, particularly when not balanced with in-person interactions. Self-monitoring and access to information empowered patients and promoted more equitable patient-provider relationships. Conclusions: Digital health technology can either strengthen or weaken patient-provider relationships in respiratory care, with effects impacted by adoption factors, confidence in technology, connection, and patient empowerment. Maintaining trust in the era of digital care requires transparent implementation of motivations, consideration of individual circumstances, and reliable technology that supports rather than replaces the therapeutic relationship. Trial Registration: PROSPERO CRD42024493664; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024493664

1 April 2019 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
SMSarah Masefield
Sarah Masefield
NCNicola Cassidy
Nicola Cassidy
DRDerek Ross
Derek Ross
PPPippa Powell
Pippa Powell
AWAthol Wells
Athol Wells
This paper explores commonalities in the experience and unmet needs of idiopathic pulmonary fibrosis (IPF) patients and carers in Europe throughout the care pathway, focusing specifically on the unmet communication needs of patients and carers.Four patient organisations/groups in Europe held focus groups (Italy (seven patients and four carers); Belgium (six patients); Ireland (23 patients and 10 carers); and England, UK (five patients and three carers)). A focus group schedule was provided and translated into the language of each focus group by the European Lung Foundation (ELF). Content analysis was conducted by the ELF and verified by the authors of the paper.Three main themes emerged: professional−patient, professional−professional and patient−patient communication. Within these themes, eight priority areas were highlighted by two or more of the focus groups. In addition, 17 suggested action points were identified.Patients and carers in Europe have unmet communication needs, which could be met by specialist physicians and specialist centres providing more effective information and signposting to support services, including support groups and patient organisations.

31 August 2011 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
YSY. Sibille
Y. Sibille
MDM. Decramer
M. Decramer
LNL.P. Nicod
L.P. Nicod
PPPaolo Palange
Paolo Palange
BNBenoit Nemery
Benoit Nemery
PPP. Powell
P. Powell